Publication Name	World Journal of Radiology
Manuscript ID	9155
Country	Netherlands

Received	2014-01-24 15:11
Peer-Review Started	2014-01-24 22:43
To Make the First Decision	2014-03-12 16:45
Return for Revision	2014-03-20 20:32
Revised
Second Decision	2014-05-19 09:10
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-19 09:28
Articles in Press	2014-05-23 12:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-11 16:30
Publish the Manuscript Online	2014-07-31 11:53

ISSN	1949-8470 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Radiology, Nuclear Medicine & Medical Imaging
Manuscript Type	Topic Highlights
Article Title	FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC
Manuscript Source	Invited Manuscript
All Author List	Matthijs H van Gool, Tjeerd S Aukema, Koen J Hartemink, Renato A Valdés Olmos, Harm van Tinteren and Houke M Klomp
Funding Agency and Grant Number
Corresponding Author	Houke M Klomp, MD, PhD, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. h.klomp@nki.nl
Key Words	Non-small cell lung cancer; Epidermal growth factor receptor-tyrosine kinase inhibitors therapy; Positron emission tomography-computed tomography; Computed tomography; Response monitoring
Core Tip	Our report shows that response monitoring using [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) acquired together with low dose computed tomography has potential in targeted treatment for non-small cell lung cancer and can be performed as early as 1-2 wk after initiation of treatment. Patients with substantial decrease of metabolic activity during epidermal growth factor receptor-tyrosine kinase inhibitors treatment will probably benefit from continued treatment. Refining FDG-PET response criteria may help the clinician to decide on continuation or discontinuation of targeted treatment.
Publish Date	2014-07-31 11:53
Citation	van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol 2014; 6(7): 392-398
URL	http://www.wjgnet.com/1949-8470/full/v6/i7/392.htm
DOI	http://dx.doi.org/10.4329/wjr.v6.i7.392

Full Article (PDF)	WJR-6-392.pdf
Full Article (Word)	WJR-6-392.doc
Manuscript File	9155-Review.docx
Answering Reviewers	9155-Answering reviewers.pdf
Copyright License Agreement	9155-Copyright assignment.pdf
Peer-review Report	9155-Peer review(s).pdf
Scientific Editor Work List	9155-Scientific editor work list.pdf